Tumour microenvironment provides the ‘soil’ for tumour growth. Besides tumour cells, there are also numbers of stromal cells, extracellular matrix and other components in the tumour microenvironment. In the past years, kinds of ligands and markers specifically high-expressed on the surface of the tumour stromal cells have been explored, which can be used as the therapeutic targets for cancer treatment. Recently, the antitumor drugs by targeting stromal cells, including small-molecular inhibitor and large-molecular monoclonal antibody, have been widely discovered and applied in clinic attributed to their specific targeting ability. Moreover, the targeted drug delivery system also paid more and more attentions due to their desired profiles in increased accumulation at tumour sites, enhanced antitumor ability and less toxicity and side effects. Therefore, it is of great significance to find and construct drug delivery systems targeting tumour stromal cells. In this review, we discussed the widely recognised therapeutic targets on tumour stromal cells, besides, the current status on the targeting drugs as well as the drug delivery systems were also highlighted.

肿瘤微环境为肿瘤生长提供了“土壤”。除了肿瘤细胞外，肿瘤微环境中还有大量的基质细胞、细胞外基质和其他成分。近年来，人们探索了多种特异性高表达于肿瘤基质细胞表面的配体和标志物，可作为癌症治疗的治疗靶点。近年来，靶向基质细胞的抗肿瘤药物，包括小分子抑制剂和大分子单克隆抗体，由于其特异性靶向能力而被广泛发现并应用于临床。此外，靶向给药系统也越来越受到关注，因为它们在肿瘤部位的积累增加、抗肿瘤能力增强以及毒性和副作用更小。因此，寻找和构建靶向肿瘤基质细胞的给药系统具有重要意义。在这篇综述中，我们讨论了广泛认可的肿瘤基质细胞治疗靶点，此外，还强调了靶向药物和给药系统的现状。